PMID: 6160354Jan 1, 1981Paper

Effects of 2-substituted 3-dimethylamino-5,6-methylenedioxyindenes on calcium-induced arrhythmias

Journal of Cardiovascular Pharmacology
J J LynchD T Witiak

Abstract

Pharmacological, biochemical, and electrophysiological studies have demonstrated that the 2-n-propyl (Pr) and 2-n-buty (Bu) 3-dimethylamino-5,6-methylenedioxyindenes (MDIs) are intracellular calcium antagonists. The MDIs exhibit coronary dilating properties in the in vitro rabbit heart and possess antiarrhythmic activity in vivo in the anesthetized ouabain-toxic dog. The results of the present investigation demonstrate that the MDIs possess significant antiarrhythmic activity against calcium-induced arrhythmias in anesthetized rats and dogs. Pretreatment of dogs with an acute dose (30 mg/kg, i.v.) of either MDI significantly delayed both the onset of intravenous infusion of calcium (500 mg/kg/hr, CaCl2 . 2H2O). Pretreatment of rats with an acute dose (3.75 mg/kg, i.v.) of either MDI provided virtually complete protection against bradycardia, arrhythmias, and death induced by an acute intravenous dose of calcium (1 ml/kg of a 10% CaCl2 . 2H2O solution. The antiarrhythmic potency of the MDIs in rats was equivalent to that of verapamil, but the latter drug produced bradycardia, electrocardiographic alterations, and atrioventricular block, whereas the MDIs exhibited no intrinsic deleterious effects of cardiac function. Prenylamine ...Continue Reading

Citations

Sep 1, 1996·Biulleten' eksperimental'noĭ biologii i meditsiny·Iu B LishmanovA V Krylatov
Apr 23, 1985·European Journal of Pharmacology·J J LynchB R Lucchesi
Jan 1, 1985·European Journal of Clinical Pharmacology·E G BreenJ A Keogh
Aug 1, 1981·Cell Calcium·F F Vincenzi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Bradyarrhythmias

Bradyarrhythmias are slow heart rates. Symptoms may include syncope, dizziness, fatigure, shortness of breath, and chest pains. Find the latest research on bradyarrhythmias here.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Cardiac Electrophysiology

Cardiac electrophysiology is the study of electrical activities of the heart and includes the assessment, diagnosis, and treatment of cardiac events. Find the latest research on cardiac electrophysiology here.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.